WARNING
Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Thiothixene is not approved for the treatment of patients with dementia-related psychosis (see WARNINGS).
|
| |
THIOTHIXENE SUMMARY
Thiothixene is a thioxanthene derivative. Specifically, it is the
cis
isomer of N,N-dimethyl-9-[3-(4-methyl-1-piperazinyl)-propylidene] thioxanthene-2-sulfonamide.
Thiothixene is effective in the management of schizophrenia. Thiothixene has not been evaluated in the management of behavioral complications in patients with mental retardation.
|
|
NEWS HIGHLIGHTSMedia Articles Related to Thiothixene
Early Cognitive Behavioural Therapy Reduces Risk Of Psychosis
Source: Mental Health News From Medical News Today [2013.04.23]
Young people seeking help who are at high risk of developing psychosis could significantly reduce their chances of going on to develop a full-blown psychotic illness by getting early access to cognitive behavioural therapy (CBT), new research shows...
In The Brain High Levels Of Glutamate May Kick-Start Schizophrenia
Source: Anxiety / Stress News From Medical News Today [2013.04.22]
An excess of the brain neurotransmitter glutamate may cause a transition to psychosis in people who are at risk for schizophrenia, reports a study from investigators at Columbia University Medical Center (CUMC) published in the current issue of Neuron...
New Gene Variant May Explain Psychotic Features In Bipolar Disorder
Source: Bipolar News From Medical News Today [2013.03.06]
Researchers at Karolinska Institutet in Sweden have found an explanation for why the level of kynurenic acid (KYNA) is higher in the brains of people with schizophrenia or bipolar disease with psychosis. The study, which is published in the scientific periodical Molecular Psychiatry, identifies a gene variant associated with an increased production of KYNA...
Published Studies Related to Thiothixene
The effect of paroxetine on thiothixene pharmacokinetics. [1997.06]
OBJECTIVE: In this study healthy volunteers received thiothixene with and without a 3-day pretreatment with paroxetine to determine if paroxetine decreased the clearance of thiothixene. METHOD: Ten healthy medication-free volunteers (4 women and 6 men, mean age 38 +/- 12 years) were randomized to receive a single 20 mg oral dose of thiothixene on two separate occasions...
A comparison of thiothixene with chlorpromazine in the treatment of mania. [1988.02]
High potency neuroleptics have been advocated for acute mania because their side effect profile may allow for a more rapid dose escalation and symptom resolution. Low potency neuroleptics have also been advocated because their sedative properties might better calm the acutely agitated manic patient...
Plasma concentrations of thiothixene and clinical response in treatment-resistant schizophrenics. [1987.01]
Plasma concentrations of thiothixene were measured during treatment of 42 treatment-resistant schizophrenic patients. Inter-individual variability was marked even when patients were treated with the same dose or dose regimen... Patients who attained moderate degrees of improvement did so at a median dose of 26 ng/ml, which is within the range of therapeutic plasma concentrations previously reported for thiothixene in similar patients.
Treatment-resistant schizophrenia: controlled study of moderate- and high-dose thiothixene. [1987.01]
Double blind controlled study on fifty treatment-resistant schizophrenic inpatients showed a statistically significant improvement in favour of the high dose group..
Clinical Trials Related to Thiothixene
Reducing Antipsychotic-Induced Weight Gain in Children With Metformin [Recruiting]
Recent but limited short term studies have shown that Metformin can slow down weight gain in
obese children and in children with psychotropic-induced weight gain, two distinct pediatric
populations that are at risk for obesity related co-morbid conditions. The purpose of this
study is to conduct a long term prospective pilot cohort study to investigate the use of
Metformin to prevent or decrease weight gain in two cohorts of children: 1) children with
psychotropic induced weight gain on Metformin and 2) children with BMI above the 95th
percentile on Metformin. Both study populations will be enrolled in a lifestyle weight
management program
|
|
|
|
Page last updated: 2013-04-23
|
